Reports
Reports
Sale
The global microbiome therapeutics market size has reached a value of more than USD 328.72 million in 2023. The market is expected to grow at a CAGR of 43.60% between 2024 and 2032, reaching a value of USD 8535.09 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
A microbiome is a group of microorganisms living in a certain environment, and in the case of humans, this term is used for microorganisms that live in or on a body part, such as the skin or gastrointestinal tract. Microbiomes are helpful in digestion, regulating the immune system, and production of essential nutrients for blood coagulation.
Microbiome therapeutics are designed to alter the gut microbiome using additives, subtractive, or modulator therapy, in addition to engineered microbes, antibiotics, and other microbes to treat human disorders.
People are increasingly adopting a sedentary lifestyle and busy work life, which has increased the prevalence of disorders due to lack of physical activities and lack of priority for physical well-being.
Due to the busy lifestyles of people and rapid urbanisation, people are shifting more and more towards packaged and junk food, which has led to a rise in obesity cases globally. The demand for microbiome therapeutics market is significantly driven by the rising cases of obesity.
Many microbiome-based product manufacturing companies have increased their focus on the development of therapeutics drugs with studies proving that the right combination of microbes with or without treatment processes can be beneficial in treating various disorders.
Growing research and developments on microbiome therapeutics and advertisement efforts have propelled the general awareness among people around the world, providing greater opportunities for the market.
Public and private organisations are increasing their efforts for strategic collaborations and partnerships to launch new and innovative products.
The regulatory requirements by current food and drug regulatory authorities are not customised for biotherapeutic products. Although regulatory organisations have authorised multiple dietary supplements that have probiotics, these products cannot be distributed for curing, mitigating, or for treatment and prevention of any diseases.
However, the authorities are planning changes in their ways of categorising probiotics, and this might prove to be extremely beneficial to the market expansion.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on type, the market can be segmented into faecal microbial transplants and drugs. Based on the application, it can be bifurcated into inflammatory bowel movement, diabetes, Crohn's disease, and clostridium difficile infection, among others. The regional markets can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global microbiome therapeutics market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments and expansion plans.
Based on type, the market segments include faecal microbiota therapy (FMT) and drugs. Among these segments, faecal microbial transplantation, also known as stool transplantation or bacteriotherapy, has held a major share in the market. It is a procedure where healthy stool or faecal matter is collected from a healthy donor and placed in the patient’s gastrointestinal tract.
This segment is expected to further develop with increasing research and development for other therapeutic applications of FMT.
The drugs segment is expected to develop at a rapid rate during the forecast period due to increasing efforts for the development of advanced and novel drugs.
Based on application, the market divisions include inflammatory bowel movement, diabetes, Crohn’s disease, and clostridium difficile infection, among others.
The clostridium difficile infection is the inflammation of the colon, which is caused by the bacteria known as clostridium difficile. This infection causes diarrhoea and colitis and results in the disruption of normal and healthy bacteria in the colon.
This segment is expected to experience significant growth due to the increasing use of faecal microbiota transplants (FMT) in the treatment of Clostridium difficile.
Crohn’s disease is a type of bowel inflammatory disease that affects the lining of a human’s digestive tract. This disease can cause abdominal pain, diarrhoea, weight loss, and anaemia. This segment is expected to go through an extensive growth with the use faecal microbiota transplantation for treatment.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Seres Therapeutics is an American-based clinical-stage therapeutics company, which was founded in 2010. Their focus lies in the development of therapeutic products and novel drugs for the treatment of diseases by targeting the human microbiome.
Rebiotix, Inc. is a biotechnology company working around clinical-stage procedures and products, and it is based in the United States and founded in 2011. The company focuses on biotechnology research for the development of microbiome-based therapeutics including human microbiome, microbiota restoration therapy, and clostridioides difficile infection. The Rebiotix company is a part of the Ferring Pharmaceuticals company.
Enterome Bioscience is a clinical-stage biopharmaceutical company specialising in immune-oncology, auto-immunity, inflammatory bowel diseases, microbiomes, metagenomics, and immunotherapies. Their company is headquartered in France, and it was founded in 2011. They have developed highly promising products, focusing on cancer and auto-immune diseases including OncoMimics and EndoMimics.
Other market players include MaaT Pharma, Vedanta Biosciences, Inc., and ABiome LLC, among others.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Type |
|
Breakup by Applications |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Microbiome Therapeutics Market Overview
3.1 Global Microbiome Therapeutics Market Historical Value (2017-2023)
3.2 Global Microbiome Therapeutics Market Forecast Value (2024-2032)
4 Global Microbiome Therapeutics Market Landscape
4.1 Global Microbiome Therapeutics Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Microbiome Therapeutics Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Applications
4.2.3 Analysis by End User
5 Global Microbiome Therapeutics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Microbiome Therapeutics Market Segmentation
6.1 Global Microbiome Therapeutics Market by Type
6.1.1 Market Overview
6.1.2 Faecal Microbial Transplant
6.1.3 Microbiome Drugs
6.2 Global Microbiome Therapeutics Market by Applications
6.2.1 Market Overview
6.2.2 Inflammatory Bowel Disease
6.2.3 Diabetes
6.2.4 Crohn’s Disease
6.2.5 Clostridium Difficile Infection
6.2.6 Others
6.3 Global Microbiome Therapeutics Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Homecare
6.3.4 Ambulatory Surgical Centers
6.3.5 Others
6.4 Global Microbiome Therapeutics Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Microbiome Therapeutics Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Microbiome Therapeutics Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Microbiome Therapeutics Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Microbiome Therapeutics Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Microbiome Therapeutics Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Seres Therapeutics
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Rebiotix, Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Enterome Bioscience
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 MaaT Pharma
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Vedanta Biosciences, Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 AOBiome LLC
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
18 Global Microbiome Therapeutics Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
In 2023, the global market for microbiome therapeutics reached a size of USD 328.72 million.
The market is expected to grow at a CAGR of 43.60% during the period 2024-2032.
The market is expected to reach a value of USD 8535.09 million.
The market is driven by the rising prevalence of sedentary lifestyles leading to increased cases of obesity and increasing research and development for human microbiome therapeutics.
Growing adoption of packed and fast foods in the diets of people and increasing awareness of microbiome therapeutics for gut disorders are among key trends driving the market growth.
The regional markets include North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The products in the market include faecal microbial transplants and drugs.
The applications available in the market include inflammatory bowel movement, diabetes, Crohn's disease, and clostridium difficile infection, among others.
The key players in the market include Seres Therapeutics, Rebiotix, Inc, Enterome Bioscience, MaaT Pharma, Vedanta Biosciences, Inc., and AOBiome LLC, among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.